Anti-idiotype antibody against anti-c-MET antibody
Disclosed are an anti-idiotype antibody that specifically binds to an idiotope site of an anti-c-Met antibody, the use of the anti-idiotype antibody for detecting the anti-c-Met antibody, and methods, polypeptides, polynucleotides, compositions, and vaccines related thereto.
1. An anti-idiotype antibody or antigen-binding fragment thereof that specifically binds to an idiotype of an anti-c-Met antibody comprising:
(a) a CDR-H1 comprising the amino acid sequence of SEP ID NO: 116, a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 126, a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 140, a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 156, a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 173, and a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 189;
(b) a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 115, a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 125, a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 139, a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 155, a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 172, and a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 188;
(c) a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 117, a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 127, a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 141, a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 157, a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 174, and a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 190;
(d) a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 118, a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 128, a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 142, a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 158, a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 175, and a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 191;
(e) a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 117, a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 129, a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 143, a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 159, a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 176, and a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 192;
(f) a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 118, a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 130, a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 144, a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 160, a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 177, and a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 193;
(g) a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 115, a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 131, a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 145, a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 161, a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 178, and a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 191;
(h) a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 116, a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 132, a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 146, a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 162, a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 178, and a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 194;
(i) a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 119, a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 133, a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 147, a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 163, a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 179, and a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 189;
(j) a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 119, a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 134, a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 148, a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 164, a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 180, and a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 195; or
(k) a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 120, a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 126, a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 149, a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 165, a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 181, and a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 196.
2. The anti-idiotype antibody or antigen-binding fragment thereof according to claim 1 , wherein the anti-idiotype antibody comprises:
a heavy chain variable region of SEQ ID NO: 202 and a light chain variable region of SEQ ID NO: 236;
a heavy chain variable region of SEQ ID NO: 203 and a light chain variable region of SEQ ID NO: 237;
a heavy chain variable region of SEQ ID NO: 204 and a light chain variable region of SEQ ID NO: 238;
a heavy chain variable region of SEQ ID NO: 205 and a light chain variable region of SEQ ID NO: 239;
a heavy chain variable region of SEQ ID NO: 206 and a light chain variable region of SEQ ID NO: 240;
a heavy chain variable region of SEQ ID NO: 207 and a light chain variable region of SEQ ID NO: 241;
a heavy chain variable region of SEQ ID NO: 208 and a light chain variable region of SEQ ID NO: 242;
a heavy chain variable region of SEQ ID NO: 209 and a light chain variable region of SEQ ID NO: 243;
a heavy chain variable region of SEQ ID NO: 210 and a light chain variable region of SEQ ID NO: 244;
a heavy chain variable region of SEQ ID NO: 211 and a light chain variable region of SEQ ID NO: 245; or
a heavy chain variable region of SEQ ID NO: 212 and a light chain variable region of SEQ ID NO: 246.
3. The anti-idiotype antibody or antigen-binding fragment thereof according to claim 1 , wherein the anti-idiotype antibody is a mouse antibody, a mouse-human chimeric antibody, a humanized antibody, or a human antibody.
4. The anti-idiotype antibody or antibody fragment thereof according to claim 1 , wherein the anti-idiotype antibody or antibody fragment thereof is an antigen-binding fragment selected from the group consisting of scFv, (scFv) 2 , Fab, Fab′, and F(ab′) 2 .
5. A composition comprising an anti-idiotype antibody or antigen-binding fragment thereof according to claim 1 and a carrier.
6. A method for detecting an anti-c-Met antibody comprising:
contacting a biological sample with an anti-idiotype antibody or antigen-binding fragment thereof according to claim 1 ; and
determining the presence or absence of an antigen-antibody reaction.
7. The method according to claim 6 , wherein the biological sample comprises serum isolated from a subject.
8. A method for analyzing an anti-drug antibody, the method comprising measuring the absorption of a serum isolated from a patient to whom a test drug has been intravenously administered; and
comparing the obtained absorption results with the absorption change of the anti-idiotype antibody or antigen-binding fragment thereof according to claim 1 in a serum isolated from a patient to whom an anti-c-Met antibody has been administered.
9. The anti-idiotype antibody or antigen-binding fragment thereof of claim 1 , wherein the anti-idiotype antibody or antigen-binding fragment thereof has an affinity (K d ) to an anti-c-Met antibody or antibody fragment of about 50 nM or less.